Moffitt tweaking master plan post purchase
Florida Business Observer – July 7
Moffitt Cancer Center completed a master facilities plan last year as it rolled out an $800 million expansion that will likely be a decade in completing. But when 10901 N. McKinley Drive, a nearly 22-acre property across the street from its existing Tampa outpatient center came on the market, the opportunity was too good to pass up.
Kids living in food deserts may be at higher risk of cancer, researchers say
TVN - July 7
“They’re eating whatever is available in the house and it can be just a bag of potato chips or pork grinds, or something bizarre like that, that I wouldn’t let my child eat ever,” Dr. Nagi Kumar, director of the Cancer Chemoprevention Program at the Moffitt Cancer Center.
John Morgan sues state for blocking the smoking of medical marijuana
Miami Herald – July 6
The Legislature did allow for edibles and “vaping” as a delivery system for THC and cannabinoids. It also provided funding for the Moffitt Cancer Center in Tampa to conduct research into the uses and effectiveness of medical marijuana.
Treating cancer with math at Moffitt Cancer Center
WTSP – July 5
It's called “mathematical oncology.” Scientists and doctors, mathematicians, at Moffitt Cancer Center are trying to take all of the variables they can, describe them with mathematical formulas about how cancer is responding to treatment in your body. This is the only place in the world that's treating cancer like this. Also seen on WINK TV, KVRR, WFTX, KXRM
Breast cancer drug gives patients more time
WQAD – July 5
Moffitt Cancer Center oncologist Dr. Heather Han says when combined with hormonal therapy, ribociclib stops signals that cancer cells use to grow and divide. "I'm obviously very excited that this drug finally actually quickly got approved, and I'm able to be there to help patients to do better," said Dr. Han.
Can Brain Tumors Run in the Family?
SELF Magazine – July 5
Peter Forsyth, M.D., chair of the Department of Neuro-Oncology at Moffitt Cancer Center, tells SELF that he’s doubtful there is a genetic link in this case, especially since the tumors arise from different forms of tissue. “Since both kinds of tumors have little to nothing in common, it is very, very unlikely that they run in families,” he says, calling it an “unusual coincidence.”
American Society for Radiation Oncology names gold medalists
Healio – July 1
The honorees — Søren M. Bentzen, DSc, PhD; Louis B. Harrison, MD, FASTRO;and Michael L. Steinberg, MD, FASTRO — will be recognized during an awards ceremony at the ASTRO Annual Meeting, which will be held Sept. 24-27 in San Diego. Harrison serves as chair of radiation oncology and deputy physician-in-chief at H. Lee Moffitt Cancer Center and Research Institute.
177 Lu-Dotatate Improves Progression-Free Survival in Advanced Progressive Midgut Neuroendocrine Tumors
ASCO Post – July Issue
In the phase III NETTER-1 trial reported in The New England Journal of Medicine, Jonathan R. Strosberg, MD, of the Moffitt Cancer Center in Tampa, Florida, and colleagues found that the addition of the targeted radiotherapeutic agent lutetium-177 (177Lu)-Dotatate to the long-acting repeatable (LAR) formulation of octreotide (Sandostatin LAR) significantly improved progression-free survival vs high-dose octreotide in patients with advanced progressive somatostatin receptor–positive midgut neuroendocrine tumors.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.